ReviewDiscover oncology2026
The role of extracellular vesicles-associated proteins markers in prostate cancer: a review.
Review in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Prostate cancer (PCa) is in the top three most common cancers among the world's male population, and its incidence has been increasing over the years. However, the primary screening and diagnostic tools still rely on serum prostate-specific antigen (PSA) and digital rectal examination (DRE), both of which have been inconclusive. Raised serum PSA and abnormal DRE findings require an invasive prostate biopsy, which has inherent surgical risk. This review aims to provide a comprehensive understanding of the biological production and properties of extracellular vesicles (EVs), which are released by all cell types, including cancer cells, and carry proteins and other biomolecules from their parent cells. EVs are becoming increasingly popular as possible biomarker candidates to improve the accuracy of diagnosing many diseases. Growing data suggest that EVs are crucial for cellular communication and tumour progression via multiple signalling pathways, including epithelial-to-mesenchymal transition (EMT), migration, and invasion, making them suitable for tracking PCa growth and metastasis. Furthermore, choosing the appropriate EV isolation method is essential to ensure accurate diagnosis. More clinically relevant, this review also identifies potential EV protein biomarkers derived from urine, serum, and tissue samples from PCa patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.